The Lifesciences Magazine

In 18 of the most dangerous malaria-affected nations, where the disease kills 600,000 people year, largely children, a new vaccine will be administered to infants. That is wonderful news. But the fervour that the announcement has aroused speaks as much to the appalling status of malaria management as it does to the genius of scientific discovery. Because this vaccine is flawed and will only protect, at most, 75% of individuals who receive it. The highest figure from the clinical trials is that one. It may only keep less than half safe in the harsh reality of rural life in impoverished areas of Africa. Because many fatalities will be prevented, it is still crucial to launch immunisation initiatives in the 18 countries that will now receive funding to do so. However, malaria is still a problem. not even close. The second vaccine to be distributed into the field is the R21/Matrix-M vaccine from Oxford University and the Serum Institute of India, which conducted the trials and will produc...

  The second-ever malaria vaccine that the World Health Organisation has advised using is a crucial component of Novavax’s (NVAX) Matrix-M, an adjuvant that aids in providing broader protection in malaria vaccines . Before the pandemic, before Novavax produced its first commercial vaccine, the COVID-19 vaccine, the adjuvant, which is licenced to the Serum Institute of India (SII) for endemic nations, had been tested in a vaccine candidate from the University of Oxford. Novavax… is proud of the role… our saponin-based Matrix-M adjuvant plays in the R21/Matrix-M malaria vaccine’, said CEO John Jacobs in a statement. According to SII CEO Adar Poonawalla, the new doses of the vaccine will be supplied by the India-based SII, the largest vaccine maker in the world, which will assist reduce demand in Africa in particular. “Unfortunately, the demand has been higher—much higher—than what other producers could reasonably supply. Therefore, the good news is that we now have a second country c...